Novartis Heart Drug Pelacarsen Fails Key Trial, Shaking Lp(a) Treatment Hopes
Novartis's Pelacarsen, a highly anticipated heart disease drug developed with Ionis Pharmaceuticals, failed its crucial Phase 3 clinical trial, sending shockwaves through the pharmaceutical industry and casting a shadow over a promising new class of therapies. The drug, aimed at treating elevated lipoprotein(a), or Lp(a), a genetic risk factor for heart disease, did not reduce major cardiovascular events like heart attacks and strokes, despite successfully lowering Lp(a) levels. This unexpected outcome marks a significant blow to a potential breakthrough treatment and led to immediate stock drops for both Novartis and its partner, Ionis Pharmaceuticals.